Results 111 to 120 of about 4,504 (155)

In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine

, 2011
Presently, therapy of eumycetoma in Sudan is still based on surgery combined with prolonged ketoconazole therapy. This usually results in a poor clinical outcome.
Ahmed H. Fahal, Laureijssen - van de Sande, Wendy, Fahal, A.H. (Ahmed), Belkum, Alex, Laureijssen - van de Sande, Wendy; id_orcid, Sande, W.W.J. (Wendy) van de, Belkum, A.F. (Alex) van, Alex van Belkum, Wendy W. J. van de Sande, Fahal, AH   +9 more
core   +1 more source

Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole

Infection and Drug Resistance, 2015
Ahmet SoysalDivision of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Marmara University, Istanbul, TurkeyAbstract: Posaconazole is a triazole antifungal agent that has broad-spectrum activity against many yeasts and ...
Soysal A
doaj  

Posaconazole as rescue therapy in African histoplasmosis

Brazilian Journal of Infectious Diseases
Posaconazole Histoplasmosis Salvage therapy African histoplasmosis is a granulomatous mycosis caused by Histoplasma capsulatum var. duboisii. Treatment is usually extrapolated from guidelines for classical histoplasmosis, and includes 2-4 weeks of ...
Daniel Gonçalves, Catarina Ferraz, Luisa Vaz   +2 more
doaj   +1 more source

The effectiveness and safety of posaconazole enteric-coated tablet versus oral suspension in invasive fungal infections

Scientific Reports
Posaconazole enteric-coated tablet and oral suspension are two oral drugs in the treatment of invasive fungal infections (IFIs). This study compared the effectiveness and safety between posaconazole enteric-coated tablet and oral suspension, and provided
Yi-Lei Yang, Qiao-Yan Yi, Yi Han, Yan Li, Rui Yang   +4 more
doaj   +1 more source

Plasma Concentrations of Prophylactic Posaconazole and Risk Factors for Subtherapeutic Exposure in Taiwanese Patients with Hematologic Malignancies

Drug Design, Development and Therapy
Hsing-Yu Lin,1,* Shu-Chen Hu,2,* Tsung-Yu Pai,1 Fang-Ju Lin,1,3,4 Chien-Chih Wu1,3 1Department of Pharmacy, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan; 2Department of Pharmacy ...
Lin HY, Hu SC, Pai TY, Lin FJ, Wu CC
doaj  

Evaluation of Posaconazole Use Within the IU Health System

, 2015
Background: Posaconazole is a broad spectrum antifungal approved for prophylaxis of invasive fungal infections caused by Candida and Aspergillosis species in immunocompromised patients and for treatment of oropharyngeal candidiasis.
Harmon, Eric
core   +1 more source

Posaconazole as rescue therapy in African histoplasmosis

Brazilian Journal of Infectious Diseases, 2013
Posaconazole Histoplasmosis Salvage therapy African histoplasmosis is a granulomatous mycosis caused by Histoplasma capsulatum var. duboisii. Treatment is usually extrapolated from guidelines for classical histoplasmosis, and includes 2-4 weeks of ...
Daniel Gonçalves, Catarina Ferraz, Luisa Vaz   +2 more
doaj  

Some of the next articles are maybe not open access.

Related searches:

Posaconazole

Drugs of Today, 2005
Invasive fungal infections are occurring with increasing frequency secondary to medical advances in the areas of transplantation, cancer management and autoimmune diseases. Unfortunately, the currently available antifungal armamentarium does not meet the increasing needs of managing infection in these complex patient populations.
Elizabeth S, Dodds Ashley, Barbara D, Alexander   +1 more
  +6 more sources

Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations [PDF]

Mycoses, 2019
Posaconazole is indicated for prophylaxis and treatment of invasive aspergillosis. Therapeutic drug monitoring (TDM) of posaconazole is used to optimise drug exposure.
Anne-Grete Martson, Edwin van den Heuvel   +1 more
exaly   +5 more sources

Safety of posaconazole

Expert Opinion on Drug Safety, 2013
The increasing number of invasive fungal infections (IFI) among immunocompromised hosts is a significant clinical issue. Diagnosis of IFI, choosing among the available antifungal drugs, and the high morbidity/mortality associated with IFI pose clinical challenges for healthcare providers.
Pauline L, Jacinto, Pranatharthi, Chandrasekar   +1 more
openaire   +2 more sources